Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
CONTEXT Schizophrenic symptoms are linked to a dysfunction of dopamine neurotransmission and the brain reward system. However, it remains unclear whether antipsychotic treatment, which blocks dopamine transmission, improves, alters, or even worsens the reward-related abnormalities. OBJECTIVE To investigate changes in reward-related brain activations in schizophrenia before and after antipsychotic monotherapy with a dopamine D2/D3 antagonist. DESIGN Longitudinal cohort study. SETTING Psychiatric inpatients and outpatients in the Capital Region of Denmark. PARTICIPANTS Twenty-three antipsychotic-naive patients with first-episode schizophrenia and 24 healthy controls initially matched on age, sex, and parental socioeconomic status were examined with functional magnetic resonance imaging while playing a variant of the monetary incentive delay task. INTERVENTIONS Patients were treated for 6 weeks with the antipsychotic compound amisulpride. Controls were followed up without treatment. MAIN OUTCOME MEASURES Task-related blood oxygen level-dependent activations as measured by functional magnetic resonance imaging before and after antipsychotic treatment. RESULTS At baseline, patients, as compared with controls, demonstrated an attenuation of brain activation during reward anticipation in the ventral striatum, bilaterally. After 6 weeks of treatment, patients showed an increase in the anticipation-related functional magnetic resonance imaging signal and were no longer statistically distinguishable from healthy controls. Among the patients, there was a correlation between the improvement of positive symptoms and normalization of reward-related activation. Those who showed the greatest clinical improvement in positive symptoms also showed the greatest increase in reward-related activation after treatment. CONCLUSIONS To our knowledge, this is the first controlled, longitudinal study of reward disturbances in schizophrenic patients before and after their first antipsychotic treatment. Our results demonstrate that alterations in reward processing are fundamental to the illness and are seen prior to any treatment. Antipsychotic treatment tends to normalize the response of the reward system; this was especially seen in the patients with the most pronounced treatment effect on the positive symptoms. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01154829.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813 · cited 1×
“The normalization in assignment of salience might be involved in the improvement of positive symptoms, as suggested in the salience hypotheses.(4,6) This is supported by the finding of the largest improvement in positive symptoms in the patients with a contrast signal increase.”
ResultSelf-citationThe Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · cited 1×
“D OPAMINE IS AN ESSENTIAL neurotransmitter in the brain reward system(1,2) and dopaminergic dysfunction has been suggested to be involved in the development of psychotic symptoms.(3) A dysregulated hyperdopaminergic state in the striatum might lead to development of psychoses through altered reward processing,(4,5) an…”
BackgroundSelf-citationThe debate over dopamine’s role in reward: the case for incentive salience
Berridge, K. C. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0578-x · Cited by 2,347
Anticipation of Increasing Monetary Reward Selectively Recruits Nucleus Accumbens
Knutson, B., Adams, C. M., Fong, G. W., & Hommer, D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-j0002.2001 · Cited by 2,244
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Self-citationAtypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Substantia nigra/ventral tegmental reward prediction error disruption in psychosis
Murray, G. K., Corlett, P. R., Clark, L., Pessiglione, M., Blackwell, A. D., Honey, G., Jones, P. B., Bullmore, E. T., Robbins, T. W., & Fletcher, P. C. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002058 · Cited by 532
Disrupted prediction-error signal in psychosis: Evidence for an associative account of delusions
Corlett, P. R., Murray, G. K., Honey, G. D., Aitken, M. R. F., Shanks, D. R., Robbins, T. W., Bullmore, E. T., Dickinson, A., & Fletcher, P. C. (2007) · Brain · doi:10.1093/brain/awm173 · Cited by 460
Dopaminergic dysfunction in schizophrenia: Salience attribution revisited
Heinz, A., & Schlagenhauf, F. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq031 · Cited by 412 · cited 1×
“Thus, the eventrelated blood oxygen level–dependent (BOLD) responses are often smaller, because phasic dopamine responses may not sufficiently differentiate from tonic dopamine levels.(9) Most cross-sectional studies in patients medicated with second-generation antipsychotics (SGAs) do not find significant changes in…”
Background
Cited by
Ventral Striatal Activation During Reward Processing in Psychosis: A Neurofunctional Meta-Analysis
Radua, J., Schmidt, A., Borgwardt, S., Heinz, A., Schlagenhauf, F., McGuire, P., & Fusar-Poli, P. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2196 · Cited by 342
Antipsychotic Treatment and Functional Connectivity of the Striatum in First-Episode Schizophrenia
Sarpal, D. K., Robinson, D. G., Lencz, T., Argyelan, M., Ikuta, T., Karlsgodt, K., Gallego, J. A., Kane, J. M., Szeszko, P. R., & Malhotra, A. K. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1734 · Cited by 327
Striatal dysfunction during reversal learning in unmedicated schizophrenia patients
Schlagenhauf, F., Huys, Q. J. M., Deserno, L., Rapp, M. A., Beck, A., Heinze, H.-J., Dolan, R., & Heinz, A. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.11.034 · Cited by 253
“Published by Elsevier Inc http://dx.doi.org/10.1016/j.neuroimage.2013.11.034 a b s t r a c t a r t i c l e i n f o”
InfluentialBarch, D. M., Pagliaccio, D., & Luking, K. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2015_376 · Cited by 218
Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment
Sarpal, D. K., Argyelan, M., Robinson, D. G., Szeszko, P. R., Karlsgodt, K. H., John, M., Weissman, N., Gallego, J. A., Kane, J. M., Lencz, T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121571 · Cited by 212
Metadata
- Authors
- Nielsen, M. O., Rostrup, E., Wulff, S., Bak, N., Broberg, B. V., Lublin, H., Kapur, S., & Glenthoj, B.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2012-12-01
- Volume
- 69
- Issue
- 12
- Pages
- 1195
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2001003983
- Cited by
- 151
- References
- 23
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia. https://app.cochat.ai/papers/10.1001/archgenpsychiatry.2012.847
- The paper
- Nielsen, M. O., Rostrup, E., Wulff, S., Bak, N., Broberg, B. V., Lublin, H., Kapur, S., & Glenthoj, B. (2012). Improvement of Brain Reward Abnormalities by Antipsychotic Monotherapy in Schizophrenia. Archives of General Psychiatry. https://doi.org/10.1001/archgenpsychiatry.2012.847
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.